This Biotech Company's Lead Candidate Treats Rare Cancers As Well As Covid-19

  • last month
Dr. Trieu, CEO of Oncotelic Therapeutics, was recently a guest on Benzinga's All Access.

Oncotelic seeks to improve the outcomes and survival of cancer patients, with a special emphasis on rare pediatric cancers. Its lead asset, OT-101, has a rare pediatric designation for diffuse intrinsic pontine glioma. The company has a host of IPs that are being studied in indications as diverse as leukemia, Parkinson’s Disease and erectile dysfunction.

Mr. Trieu spoke about the nanomedicine platform his company is currently building out.

Recommended